Cancer cells originate from a series of acquired genetic mutations that can drive their
uncontrolled cell proliferation and immune evasion. Environmental factors, including the …

There is an increasing appreciation for the heterogeneous nature of extracellular vesicles
(EVs). In addition, two nonvesicular extracellular nanoparticles (NVEPs), exomeres and …

The success of messenger RNA therapeutics largely depends on the availability of delivery
systems that enable the safe, effective and stable translation of genetic material into …

Extracellular vesicles (EVs) are gaining increasing attention for diagnostic and therapeutic
applications in various diseases. These natural nanoparticles benefit from favorable safety …

Exosomes (EXOs) have been proven as biomarkers for disease diagnosis and agents for
therapeutics. Great challenge remains in the separation of EXOs with high-purity and low …

Extracellular vesicles (EVs) are nano-sized, natural, cell-derived vesicles that contain the
same nucleic acids, proteins, and lipids as their source cells. Thus, they can serve as natural …

Paclitaxel (PTX)-based chemotherapy remains the main approach to treating lung cancer
but systemic toxicity limits its use. As chimeric antigen receptor-T (CAR-T) cell-derived …

Cell-based therapy holds great potential to address unmet medical needs and revolutionize
the healthcare industry, as demonstrated by several therapeutics such as CAR-T cell …

Extracellular vesicles (EVs) are gaining ground as next-generation drug delivery modalities.
Genetic fusion of the protein of interest to a scaffold protein with high EV-sorting ability …

Extracellular vesicles (EVs) have increasingly been recognized as important cell surrogates
influencing many pathophysiological processes, including cellular homeostasis, cancer …